GET THE APP

Mesenchymal stem cells in clinical applications
..

Journal of Tissue Science and Engineering

ISSN: 2157-7552

Open Access

Mesenchymal stem cells in clinical applications


7th International Conference on Tissue Engineering & Regenerative Medicine

October 02-04, 2017 Barcelona, Spain

Brian M Mehling

Blue Horizon International, USA

Keynote: J Tissue Sci Eng

Abstract :

Mesenchymal stem cells (MSCs), multipotent adult stem cells, feature the potential to regenerate tissue damage and inhibit inflammation. Our research studies designed to measure the safety and efficacy of intravenous, intra-articular and intrathecal stem cell therapies. Retrospective chart review study of umbilidal cord blood (UCB) stem cell therapy for spinal cord injury showed that significantly higher proportion of patients in the stem cell therapy group showed improved function in pain and temperature sensation, lower limb muscle strength, bladder and gastrointestinal function compared to the traditional therapy group. UCB stem cell therapy of patients with sequelae of cerebrovascular hemorrhage and CVA (Stroke) sequelae showed significant improvement of mobility and muscule strength of upper and lower extremities, improvement of neurological function. In the period from 2015 to 2016, 207 subjects with musculoskeletal conditions underwent the therapy with their own stromal vascular fraction cells. Analysis of subjects� pain sensation and mobility showed the following: ten days after the therapy, pain sensation decreased by 26.8%. Three months after therapy, the number of subjects with a decrease in pain sensation increased to 50.0%, and six months later, this number was 52.5%. Analysis of subjects� mobility showed the following: ten days after the therapy, mobility was improved at 26.0%. Three months after therapy, the number of subjects with improved mobility increased to 43.8%, and six months later this number was 47.4%. Statistical analysis showed that the decrease in subjects� pain sensation and improvement of subjects� mobility three and six months after the therapy was statistically significant.

Biography :

Brian M Mehling is a practicing American Orthopedic Trauma Surgeon, Researcher, and Philanthropist. He has started his path in Medicine through under-graduate study at Harvard University. He has obtained his Bachelor of Arts and Master of Science degrees in Biochemistry from Ohio State University. He has completed his degree of Medicine at Wright State University School of Medicine. He has received his Post-graduate education through residencies and fellowships at St. Joseph’s Hospital in Paterson, N J and the Graduate Hospital in Philadelphia, P A, while pursuing a PhD in Chemistry. He operates his own practice, Mehling Orthopedics, in both West Islip, N Y and Hackensack, N J.

Google Scholar citation report
Citations: 807

Journal of Tissue Science and Engineering received 807 citations as per Google Scholar report

Journal of Tissue Science and Engineering peer review process verified at publons

Indexed In

 
arrow_upward arrow_upward